RHJA
TVTX icon

Rice Hall James & Associates’s Travere Therapeutics TVTX Stock Holding History

Rice Hall James & Associates’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.54M Buy
97,573
+4,816
+5% +$214K 0.27% 93
2026
Q1 		$2.76M Buy
92,757
+1,221
+1% +$36.5K 0.15% 140
2025
Q4 		$3.5M Buy
91,536
+7,439
+9% +$242K 0.19% 116
2025
Q3 		$2.01M Sell
84,097
-9,515
-10% -$179K 0.11% 161
2025
Q2 		$1.39M Buy
93,612
+4,995
+6% +$82.8K 0.07% 187
2025
Q1 		$1.59M Sell
88,617
-4,041
-4% -$82K 0.09% 178
2024
Q4 		$1.61M Sell
92,658
-2,078
-2% -$36.8K 0.09% 190
2024
Q3 		$1.33M Buy
94,736
+18,562
+24% +$193K 0.07% 198
2024
Q2 		$626K Buy
76,174
+2,774
+4% +$18.7K 0.04% 220
2024
Q1 		$566K Buy
73,400
+3,140
+4% +$26.5K 0.03% 228
2023
Q4 		$632K Sell
70,260
-8,102
-10% -$59K 0.04% 236
2023
Q3 		$701K Sell
78,362
-1,481
-2% -$20.9K 0.04% 229
2023
Q2 		$1.23M Buy
79,843
+3,345
+4% +$60.8K 0.07% 205
2023
Q1 		$1.72M Buy
76,498
+290
+0.4% +$6.16K 0.1% 200
2022
Q4 		$1.6M Sell
76,208
-1,629
-2% -$34.5K 0.09% 210
2022
Q3 		$1.92M Sell
77,837
-24,154
-24% -$624K 0.11% 190
2022
Q2 		$2.47M Buy
101,991
+2,428
+2% +$61.1K 0.12% 172
2022
Q1 		$2.57M Buy
99,563
+3,387
+4% +$89.9K 0.1% 188
2021
Q4 		$2.98M Sell
96,176
-13,030
-12% -$367K 0.11% 176
2021
Q3 		$2.65M Buy
109,206
+2,379
+2% +$43.7K 0.1% 159
2021
Q2 		$1.56M Sell
106,827
-5,073
-5% -$100K 0.06% 233
2021
Q1 		$2.79M Buy
111,900
+36
+0% +$995 0.09% 156
2020
Q4 		$3.05M Buy
+111,864
New +$2.61M 0.11% 141

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rice Hall James & Associates's TVTX Position: Q2 2026 in Review

Rice Hall James & Associates increased its Travere Therapeutics (TVTX) stake by 5.2% in Q2 2026, buying an estimated $214K and bringing the position to 97,573 shares worth $5.54M. The position accounts for 0.27% of the portfolio, ranked #93.

Rice Hall James & Associates first reported a position in TVTX in Q4 2020 and has held it in 23 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Rice Hall James & Associates held 97,573 shares of Travere Therapeutics worth $5.54M as of Q2 2026.
  • Rice Hall James & Associates bought 4,816 Travere Therapeutics shares in Q2 2026, an estimated $214K.
  • Travere Therapeutics made up 0.27% of Rice Hall James & Associates's portfolio in Q2 2026, its #93 holding.
  • Rice Hall James & Associates first reported a position in Travere Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.